Thu. 9 May 2024, 7:38am ET
Benzinga
Earnings, Earnings Beats, News
Larimar Therapeutics (NASDAQ:LRMR) reported quarterly losses of $(0.27) per share which beat the analyst consensus estimate of $(0.28) by 3.57 percent. This is a 80 percent decrease over losses of $(0.15) per share from the same period last year.